Search

Displaying results 1831 - 1840 of 8468 in total
  1. Drug

    Phosphoric acid

    go.drugbank.com/drugs/DB09394
    ApprovedInvestigational

    Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.

  2. Drug

    Ferric cation

    go.drugbank.com/drugs/DB13949
    ApprovedWithdrawn

    Iron deficiency may be characterized without the development of anemia, and may result in functional impairments affecting cognitive development and immunity mechanisms, as well as infant or maternal mortality

  3. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    [L36773] In 1998, mafenide acetate was approved under the FDA’s accelerated approval regulations. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  4. Drug

    Calcium gluconate

    go.drugbank.com/drugs/DB11126
    ApprovedInvestigationalVet approved

    Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet.

  5. Drug

    Calcium Phosphate

    go.drugbank.com/drugs/DB11348
    ApprovedInvestigational

    Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] [L851].

  6. Drug

    Milrinone

    go.drugbank.com/drugs/DB00235
    ApprovedInvestigational

    [A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483] … [A228338, A11759, A228323, A228333, A228348, L31483] Milrinone was originally synthesized at the Sterling Winthrop Research Institute in the 1980s.

  7. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the … Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma

  8. Drug

    Cefoperazone

    go.drugbank.com/drugs/DB01329
    ApprovedInvestigationalWithdrawn

    While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.

  9. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder. … Gene therapy with autologous hematopoietic stem cells was introduced and investigated as a possible treatment for patients with adrenoleukodystrophy.

  10. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].